Shares in Fate Therapeutics (Nasdaq: FATE) are up more than a tenth after the cellular immunotherapy specialist unveiled a global collaboration and option agreement with Johnson & Johnson (NYSE: JNJ).
J&J’s pharma arm, Janssen, will contribute proprietary antigen binding domains as part of an R&D project aimed at developing novel CAR-NK and CAR-T Cell product candidates.
Fate Therapeutics will use its iPSC product platform to research and preclinically develop the candidates, and will receive $50 million in cash and $50 million for an equity stake at $30 per share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze